Anti-HER2 antibodies
The target, and what it means for safety
HER2 is a receptor tyrosine kinase in the epidermal growth factor receptor family, involved in signalling for proliferation and survival. Antibodies against it are used in tumours that overexpress it. The feature that shapes nonclinical work in this class is that the target is not confined to tumour tissue: it is expressed in normal tissue as well, and that is the origin of the toxicity the class is known for.
The approved antibodies and how they differ structurally
Trastuzumab
Trastuzumab was approved in September 1998.[S1] Its prescribing information carries a boxed warning covering cardiomyopathy, infusion reactions, embryo-fetal toxicity and pulmonary toxicity.[S1] The first of those is the one that determines how a nonclinical programme in this class is designed, for reasons set out below.
Pertuzumab
Pertuzumab was approved in June 2012.[S2] It binds a different epitope on the same receptor and acts on dimerization rather than on the same interaction trastuzumab addresses. Two antibodies against one target, binding different epitopes, is the point of interest here: epitope choice is a design variable with consequences for both activity and the species in which activity can be demonstrated.
Margetuximab
Margetuximab was approved in December 2020, and its prescribing information describes it as a chimeric Fc-engineered immunoglobulin G1 kappa monoclonal antibody.[S3] Fc engineering alters how the antibody interacts with Fc receptors on immune cells. For nonclinical work this matters in a specific way: Fc receptor biology differs between species, so an engineered Fc that behaves one way in a human cell system may behave differently in the animal used for toxicology.
The problems specific to this class
Expression is heterogeneous
A review of HER2 heterogeneity describes it as significant at temporal, spatial and molecular levels.[S7] For a nonclinical study the consequence is that a cell line engineered to overexpress the receptor uniformly represents an idealized case rather than a tumour. Where the question involves lower or uneven expression, the model has to contain that, which points toward patient-derived material and toward pathology readouts that report distribution rather than an average.
Resistance
Resistance mechanisms described for this class include signalling through pathways that bypass the receptor, loss of receptor expression, and changes in how the antibody is internalized. For nonclinical work the practical question is whether a resistant line is available and how it was derived, since a line made resistant by prolonged exposure in culture and one derived from a patient after treatment are different objects and support different conclusions.
Target-related cardiotoxicity
Two features complicate evaluation. Activity depends in part on immune effector function, so a study in an immunodeficient animal measures only the direct signalling effect. And the cardiac toxicity associated with this class arises from the target itself rather than from an off-target interaction, which changes what nonclinical work can do about it.
Why the cardiotoxicity cannot be designed out
The mechanism is documented. Neuregulin 1 exerts cardioprotective effects through its interaction with ErbB2 and ErbB4 on cardiomyocytes,[S4] and blocking ErbB2, which is HER2, interferes with that protection. A narrative review describes trastuzumab as the best-characterized antibody associated with cancer therapy-related cardiac dysfunction.[S5] The same signalling axis appears in a different drug class: a review of cardiotoxicity with an EGFR inhibitor describes disruption of the neuregulin and ErbB axis as causing comparable reversible dysfunction to that seen with trastuzumab.[S6] The practical consequence is that this is a target-related effect, not a molecule-specific one. Nonclinical work cannot screen it away by choosing a better antibody; it can characterize the exposure at which it appears and establish what to monitor. Cardiovascular assessment under the safety pharmacology guidance is where that is done.[S9]
The nonclinical work
Models that reproduce the expression pattern
Cell lines with defined expression levels establish the concentration-response relationship cleanly. Patient-derived models and organoids retain uneven expression, which is what the clinical population presents.[S7] Using both answers different questions: the first establishes whether the antibody works at all against the target, the second whether it works when only some cells carry it.
Separating direct signalling from immune-mediated activity
Target engagement and antibody-dependent cell-mediated cytotoxicity are separate contributions and are measured separately, because a construct optimized for one may not be optimized for the other. Flow cytometry, receptor occupancy measurement and quantitative pathology are the usual methods. Where the Fc region has been engineered, the effector function assay carries more weight, since that is what the engineering was for.[S3]
Pharmacokinetics and tumour distribution
Plasma concentration establishes systemic exposure; it does not establish how much antibody reached the tumour interior. Antibodies penetrate solid tumours unevenly, and a high plasma concentration is compatible with poor penetration. Measuring distribution within the tumour, rather than in a homogenate, is what distinguishes the two situations.
Safety assessment
Cardiac assessment is the priority for the reason set out above, and it is conducted under the safety pharmacology guidance.[S9] Immunogenicity, meaning the formation of anti-drug antibodies, is assessed because it affects exposure in the repeat-dose studies themselves and can make later timepoints uninterpretable. Note that ion channel assays developed for small molecules address a different mechanism from the target-related cardiac effect described here, and one does not substitute for the other.
Species selection comes first
For a biologic the toxicology programme is built on a species in which the product is pharmacologically active, which the guidance on biotechnology-derived pharmaceuticals addresses.[S8] An antibody raised against human HER2 may not bind the rodent receptor with useful affinity, in which case rodent toxicology reports the effect of an inactive protein. This determines the entire package and is established experimentally, by measuring binding and functional activity across candidate species, before the toxicology plan is written rather than after.
What to establish with the laboratory
Four things are worth establishing before award. Whether the laboratory has measured binding and functional activity of antibodies against this target across species, since that determines the toxicology plan.[S8] Which models it holds at which expression levels, including any with uneven expression. Whether it runs effector function assays with human immune cells and how the donors are handled. And how cardiac function will be assessed in the repeat-dose studies, given that the effect in this class is target-related.[S4][S9]
About this article
This is an independent editorial article for people who commission nonclinical work in the United States. Product characteristics and warnings are taken from the prescribing information as published, and approvals are recorded as facts; this site does not discuss the efficacy of any product or compare products. It does not recommend any laboratory. Last reviewed: September 3, 2026.
References
- FDA — HERCEPTIN (trastuzumab) approval record and full prescribing information（BLA 103792、1998/9/25 approval）. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-09-03)
- FDA — PERJETA (pertuzumab) approval record（BLA 125409、2012/6/8 approval）. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-09-03)
- FDA — MARGENZA (margetuximab-cmkb) Description and approval record（BLA 761150、2020/12/16 approval）. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-09-03)
- Cardioprotective Role of Neuregulin1-ErbB2 Signaling Pathway: Its Physiological and Onco-Cardiologic Implications. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
- Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
- Osimertinib-Associated Cardiotoxicity in EGFR-Mutant Non-Small Cell Lung Cancer: Mechanisms, Phenotypes. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
- HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies. https://pubmed.ncbi.nlm.nih.gov/ (accessed 2026-09-03)
- FDA — ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals (accessed 2026-09-03)
- FDA — S7A Safety Pharmacology Studies for Human Pharmaceuticals. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s7a-safety-pharmacology-studies-human-pharmaceuticals (accessed 2026-09-03)
Japanese
